Thompson Davis & Co’s Amicus Therapeutics FOLD Stock Holding History

Thompson Davis & Co’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	$30K	Sell	2,444 -383	-14%	-$5.36K	0.07%	278
2018 Q2	$44K	Hold	2,827	–	–	0.1%	213
2018 Q1	$43K	Hold	2,827	–	–	0.11%	186
2017 Q4	$41K	Buy	2,827 +2,452	+654%	+$33.7K	0.1%	208
2017 Q3	$6K	Buy	+375	New	+$4.96K	0.01%	809
2015 Q4	–	Sell	-10,250	Closed	-$143K	–	1149
2015 Q3	$143K	Hold	10,250	–	–	0.2%	116
2015 Q2	$145K	Sell	10,250 -300	-3%	-$3.61K	0.17%	141
2015 Q1	$115K	Buy	10,550 +5,550	+111%	+$48.9K	0.14%	161
2014 Q4	$42K	Buy	5,000 +4,000	+400%	+$27.5K	0.05%	314
2014 Q3	$6K	Buy	+1,000	New	+$5.24K	0.01%	837

Other funds holding FOLD

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Thompson Davis & Co's FOLD Position: Q3 2018 in Review

Thompson Davis & Co reduced its Amicus Therapeutics (FOLD) stake by 14% in Q3 2018, selling an estimated $5.36K and leaving 2,444 shares worth $30K. The position accounts for 0.07% of the portfolio, ranked #278.

Thompson Davis & Co first reported a position in FOLD in Q3 2014 and has held it in 10 quarters since. The position peaked at $145K in Q2 2015. 204 funds tracked by Wall St. Rank hold FOLD as of Q3 2018.

Thompson Davis & Co held 2,444 shares of Amicus Therapeutics worth $30K as of Q3 2018.
Thompson Davis & Co sold 383 Amicus Therapeutics shares in Q3 2018, an estimated $5.36K.
Amicus Therapeutics made up 0.07% of Thompson Davis & Co's portfolio in Q3 2018, its #278 holding.
Thompson Davis & Co first reported a position in Amicus Therapeutics in Q3 2014 and has held it in 10 quarters since.
Thompson Davis & Co's Amicus Therapeutics position peaked at $145K in Q2 2015.
204 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.